AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.032

+0.0026.67%

Volume:16.08M

Turnover:503.52K

Market Cap:74.69M

PE:-0.85

High:0.033

Open:0.030

Low:0.030

Close:0.030

Loading ...

Overview Company News Filings

Radiopharm Theranostics Secures Ethics Approval to Expand Phase 1 Cancer Trial; Shares Up 4%

MT Newswires Live

Radiopharm extends radioimmunotherapy trial to 5 more cancer types

The Market Herald

Radiopharm Theranostics Ltd-Approval Received to Expand Rad204 Phase 1 Trial

THOMSON REUTERS

Smallcap Radiopharm notches +12% jump on pancreatic cancer imaging win

The Market Herald

Radiopharm Theranostics Teams Up with AtomVie Global Radiopharma for Antibody Development; Shares Up 4%

MT Newswires Live

BRIEF-Radiopharm Theranostics Partners With Atomvie

Radiopharm Theranostics Ltd - Rad Partners With Atomvie to Develop B7h3 Trial Doses

THOMSON REUTERS

Radiopharm Theranostics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

Market Sentiment Around Loss-Making Radiopharm Theranostics Limited (ASX:RAD)

Simply Wall St.

Radiopharm Theranostics Non-Executive Director Acquires 430% More Stock

Simply Wall St.

BRIEF-Radiopharm Theranostics Launches American Depositary Receipt Program

Radiopharm Theranostics Ltd - Each Ads Represents 200 Ordinary Shares of Co

THOMSON REUTERS

Radiopharm Theranostics Ltd - Launching American Depositary Receipt Program

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/RAD.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RAD.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.032,"timestamp":1741583520000,"preClose":0.03,"halted":0,"volume":16084721,"delay":0,"changeRate":0.066667,"change":0.002,"floatShares":1544866590,"shares":2333980142,"eps":-0.037714,"lyrEps":-0.124072,"pbRate":1.4,"amount":503521,"amplitude":0.1,"volumeRatio":0.8296460766963204,"dividePrice":0,"prevYearClose":0.024,"fiveDayClose":0.026,"twentyDayClose":0.025},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":1544866590,"roa":"-28.87%","roe":"-112.21%","lyrEps":-0.124072,"volumeRatio":0.8296460766963204,"shares":2333980142,"dividePrice":0,"high":0.033,"amplitude":0.1,"preClose":0.03,"low":0.03,"week52Low":0.021,"pbRate":"1.40","psRate":"172.97","week52High":0.063,"institutionHeld":0,"latestPrice":0.032,"committee":0.037075,"eps":-0.037714,"divideRate":0,"volume":16084721,"delay":0,"ttmEps":-0.037714,"open":0.03,"prevYearClose":0.024,"prevWeekClose":0.03,"prevMonthClose":0.026,"prevQuarterClose":0.024,"fiveDayClose":0.026,"twentyDayClose":0.025,"sixtyDayClose":0.033},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2484957237","title":"Radiopharm Theranostics Secures Ethics Approval to Expand Phase 1 Cancer Trial; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484957237","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484957237?lang=en_us&edition=fundamental","pubTime":"2024-11-19 12:07","pubTimestamp":1731989270,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics (ASX:RAD) secured regulatory approval to expand its phase 1 trial investigating the safety and tolerability of 177Lu-RAD204, a treatment candidate for non-small cell lung cance","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LU1043141123.HKD","LU0994945656.USD","XAO.AU","LU0426412945.USD","RAD.AU","LU2238339852.HKD","XKO.AU","AUD","LU0345774631.USD","BK4125","XJO.AU","LU0426417589.USD"],"gpt_icon":0},{"id":"2484957991","title":"Radiopharm extends radioimmunotherapy trial to 5 more cancer types","url":"https://stock-news.laohu8.com/highlight/detail?id=2484957991","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484957991?lang=en_us&edition=fundamental","pubTime":"2024-11-19 11:55","pubTimestamp":1731988500,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd  has received approval from the Australian Ethics Committee to expand its trial to assess the safety and tolerability of its antibody Lu-RAD204, meaning the treatment will be assessed with regard to five more tumour types.The main function of RAD204 – a single domain monoclonal antibody – is its targeting of PD-L1, a protein which helps control the immune system and is overexpressed in many solid cancers.Radiopharm has been progressing a Phase 1 clinical trial to assess how Lu-labelled RAD204 is tolerated for the treatment of PD-L1 expressing cancers, and as per the approval notice, this will now include participants with Programmed Death-Ligand 1  positive Small Cell Lung Cancer , Triple Negative Breast Cancer , Melanoma, Head and Neck Cancer , and Endometrial Cancer.“The implications of including additional PD-L1 expressing tumor types beyond NSCLC in this study is far-reaching,” he said.“Patients with five additional PD-L1 expressing tumor types are now e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/radiopharm-extends-radioimmunotherapy-trial-to-5-more-cancer-types-2024-11-19/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["XKO.AU","XAO.AU","XJO.AU","BK7067","RAD.AU"],"gpt_icon":0},{"id":"2484955828","title":"Radiopharm Theranostics Ltd-Approval Received to Expand Rad204 Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2484955828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484955828?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:04","pubTimestamp":1731981844,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUE4XRYZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2484066699","title":"Smallcap Radiopharm notches +12% jump on pancreatic cancer imaging win","url":"https://stock-news.laohu8.com/highlight/detail?id=2484066699","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484066699?lang=en_us&edition=fundamental","pubTime":"2024-11-18 08:32","pubTimestamp":1731889920,"startTime":"0","endTime":"0","summary":"The overall profile of Radiopharm Theranostics’  pancreatic cancer imaging drug RAD 301 has this week been boosted by a published study.The study by Dresden-based Dr. Jana Rehm, which ran in the ‘Frontiers in Nuclear Medicine’ journal, supported the use of RAD 301  in imaging pancreatic cancers based on data the study used.Titled “αvβ6-integrin targeted PET/CT imaging in pancreatic cancer patients using68Ga-Trivehexin,” the paper noted RAD 301 detected 40 pancreatic cancers, with authors concluding “[suitability] for imaging of … pancreatic cancer due to its ability to distinguish primary carcinoma and metastases from background tissue.”In the company’s words, a “high tumor-to-background ratio” was noted for RAD 301 when detecting cancers within the human pancreas.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/smallcap-radiopharm-notches-12-jump-on-pancreatic-cancer-imaging-win-2024-11-18/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","RAD.AU"],"gpt_icon":1},{"id":"2475623033","title":"Radiopharm Theranostics Teams Up with AtomVie Global Radiopharma for Antibody Development; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475623033","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475623033?lang=en_us&edition=fundamental","pubTime":"2024-10-16 09:41","pubTimestamp":1729042885,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  and AtomVie Global Radiopharma partnered with Radiopharm Ventures to develop and manufacture the 177Lu-BetaBart radio-antibody for treating solid tumors, according to a Wednesday filing with the Australian Securities Exchange.The first-in-human therapeutic trial with 177Lu-BetaBart is set to start in the US in 2025, the filing said.Radiopharm Ventures is a joint venture between Radiopharm Theranostics and MD Anderson Cancer Center in Texas, according to the filing.Shares of Radiopharm Theranostics rose nearly 4% in midday trade.Price : $0.03, Change: $+0.0010, Percent Change: +3.85%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4125","AUD","RAD.AU","BK7067"],"gpt_icon":0},{"id":"2475546641","title":"BRIEF-Radiopharm Theranostics Partners With Atomvie","url":"https://stock-news.laohu8.com/highlight/detail?id=2475546641","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475546641?lang=en_us&edition=fundamental","pubTime":"2024-10-16 08:39","pubTimestamp":1729039155,"startTime":"0","endTime":"0","summary":"Oct 16 (Reuters) - Radiopharm Theranostics Ltd   :   * RAD PARTNERS WITH ATOMVIE TO DEVELOP B7H3 TRIAL DOSES Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2475757694","title":"Radiopharm Theranostics Ltd - Rad Partners With Atomvie to Develop B7h3 Trial Doses","url":"https://stock-news.laohu8.com/highlight/detail?id=2475757694","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475757694?lang=en_us&edition=fundamental","pubTime":"2024-10-16 05:24","pubTimestamp":1729027485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nFWN3LR1AF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2472507873","title":"Radiopharm Theranostics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2472507873","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472507873?lang=en_us&edition=fundamental","pubTime":"2024-10-03 04:48","pubTimestamp":1727902121,"startTime":"0","endTime":"0","summary":"ASX:RAD Earnings and Revenue History October 2nd 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates significantly. Earnings per share  missed analyst estimates by 22%.Looking ahead, revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Biotechs industry in Australia.The company's shares are down 9.7% from a week ago.It's necessary to consider the ever-present spectre of investment risk.   We've identified 4 warning signs  with Radiopharm Theranostics , and understanding these should be part of your investment process.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/radiopharm-theranostics-full-2024-earnings-204841510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RAD.AU"],"gpt_icon":0},{"id":"2470628510","title":"Market Sentiment Around Loss-Making Radiopharm Theranostics Limited (ASX:RAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2470628510","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470628510?lang=en_us&edition=fundamental","pubTime":"2024-09-25 11:10","pubTimestamp":1727233827,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse Radiopharm Theranostics Limited's ( ASX:RAD ) business as it appears the...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rad/radiopharm-theranostics-shares/news/market-sentiment-around-loss-making-radiopharm-theranostics","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RAD","RAD.AU","BK7067","BK4128"],"gpt_icon":0},{"id":"2469042206","title":"Radiopharm Theranostics Non-Executive Director Acquires 430% More Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2469042206","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469042206?lang=en_us&edition=fundamental","pubTime":"2024-09-21 04:57","pubTimestamp":1726865852,"startTime":"0","endTime":"0","summary":"Potential Radiopharm Theranostics Limited  shareholders may wish to note that the Non-Executive Director, Ian Turner, recently bought AU$150k worth of stock, paying AU$0.04 for each share. We reckon that's a good sign, especially since the purchase boosted their holding by 430%.The Last 12 Months Of Insider Transactions At Radiopharm Theranostics. Notably, that recent purchase by Ian Turner is the biggest insider purchase of Radiopharm Theranostics shares that we've seen in the last year. That means that an insider was happy to buy shares at above the current price of AU$0.032. Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.Radiopharm Theranostics insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depic","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/radiopharm-theranostics-non-executive-director-205732503.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RAD.AU","BK7067"],"gpt_icon":1},{"id":"2468939665","title":"BRIEF-Radiopharm Theranostics Launches American Depositary Receipt Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2468939665","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468939665?lang=en_us&edition=fundamental","pubTime":"2024-09-19 09:07","pubTimestamp":1726708071,"startTime":"0","endTime":"0","summary":"Sept 19 (Reuters) - Radiopharm Theranostics Ltd :   * LAUNCHING AMERICAN DEPOSITARY RECEIPT PROGRAM   * EACH ADS REPRESENTS 200 ORDINARY SHARES OF COFurther company coverage:","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2468562644","title":"Radiopharm Theranostics Ltd - Each Ads Represents 200 Ordinary Shares of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2468562644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468562644?lang=en_us&edition=fundamental","pubTime":"2024-09-19 08:00","pubTimestamp":1726704004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240919:nFWN3L00VR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2468556266","title":"Radiopharm Theranostics Ltd - Launching American Depositary Receipt Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2468556266","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468556266?lang=en_us&edition=fundamental","pubTime":"2024-09-19 08:00","pubTimestamp":1726704004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240919:nFWN3L00VR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":3,"totalSize":45}]}}